Picture of Corvus Pharmaceuticals logo

CRVS — Corvus Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Corvus Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

* Corvus Pharmaceuticals Inc  CRVS.OQ  reported a quarterly
adjusted loss of 60 cents​​ per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -12 cents.  The mean expectation of
five analysts for the quarter was for a loss of 11 cents per
share. Wall Street expected results to range from -14 cents
to -10 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 60 cents​.
    * The company reported a quarterly loss of $40.22 million.
    * Corvus Pharmaceuticals Inc shares had risen by 81.1% this
quarter and gained 443.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is 10.00 
This summary was machine generated from LSEG data November 12 at
11:28 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.11          -0.60          Missed
 Jun. 30 2024      -0.11          -0.04          Beat
 Mar. 31 2024      -0.13          -0.12          Beat
 Dec. 31 2023      -0.12          -0.14          Missed

Recent news on Corvus Pharmaceuticals

See all news